Efficacy of Ivermectin in Outpatients With Non-severe COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Coronavirus Infection
- COVID-19
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This is a double blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing hospitalization in outpatients with COVID-19.Masking: Triple (Participant, Investigator, Outcomes Assessor)Masking Description: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a randomized controlled trial to evaluate the efficacy of ivermectin in COVID-19 outpatients reducing the risk of progression to severe disease. Patients with COVID-19 infection are randomized to receive a single dose of 200mcg/kg of ivermectin or a placebo. The randomization code is generat...
This is a randomized controlled trial to evaluate the efficacy of ivermectin in COVID-19 outpatients reducing the risk of progression to severe disease. Patients with COVID-19 infection are randomized to receive a single dose of 200mcg/kg of ivermectin or a placebo. The randomization code is generated by the trial statistician. The allocation is made after fulfilment of both inclusion and exclusion criteria.
Tracking Information
- NCT #
- NCT04834115
- Collaborators
- Consejo Nacional de Ciencias y Tecnologia, Paraguay
- Ministerio de Salud Pública y Bienestar Social, Paraguay
- Centro de información y recursos para el desarrollo, Paraguay
- Centro para el Desarrollo de la Investigación Científica, CEDIC, Paraguay
- Instituto Desarrollo, Paraguay
- Investigators
- Not Provided
Get Well Soon